Business Wire

SD Worx Chooses Talkdesk Contact Center Solution

Share

Talkdesk®, Inc., a global contact center leader for customer-obsessed companies, and Microsoft are partnering to deliver a contact center solution for SD Worx. The leading European provider of people solutions selected Talkdesk with Microsoft Teams Connector because it will provide a future-proof platform with enhanced stability to support better customer experiences (CX) through richer agent collaborations.

With headquarters in Belgium, SD Worx has been delivering people solutions across the entire employee lifecycle for more than 75 years. Turning human resources (HR) into a source of value for their more than 80,000 clients across 150 plus countries worldwide, company leaders believe people are at the heart of any business success. SD Worx is driven by a desire to see not only their own global workforce of nearly 7,000 thrive and spark success, but also the five million plus employees they serve each month.

The existing SD Worx contact center operates with separate telephony and case management platforms. Those separate platforms, paired with a combined inbound and outbound volume of more than a million client calls each year, make the process for agents trying to simultaneously gather client insights and field client queries complicated.Talkdesk CX Cloud™, an end-to-end customer experience solution, will provide SD Worx with a modernized, cloud-based contact center platform that can grow with the company.

Additionally, Talkdesk Microsoft Teams Connector™ will enable deeper collaboration between contact center agents and other teams across the organization. Talkdesk for Salesforce™ will further streamline operations and enhance opportunities for personalized engagement across channels. The Talkdesk solution – providing deep integrations with these key platforms – will allow SD Worx agents to more proactively support clients with increased efficiency.

“When we design our contact center flows, I always try to picture myself as one of our clients,” said Yannick Lefever, product owner, SD Worx. “CX comes first here. It’s important to us that the whole customer journey is positive and productive from inquiry to conclusion, and the little details can make or break that experience for all involved. The Talkdesk solution will provide a more seamless experience for SD Worx agents and clients, ensuring that all those details align across platforms and customer touch points.”

“At Microsoft, we strive to exceed customer expectations,” said Mauro Xavier, general manager for partnership solutions, Microsoft. “Partnerships like the one we have with Talkdesk allow us to do exactly that. By integrating best in breed software – Talkdesk CX Cloud and Microsoft Teams – we were able to provide a unique value proposition to SD Worx, enhancing collaboration and enabling a better user experience.”

“For any industry – and especially people solutions – a successful, customer-centric approach to contact center operations hinges on the ability for departments, teams, and individual contact center agents to collaborate seamlessly,” said Tiago Paiva, chief executive officer, Talkdesk. “With the Talkdesk solution, SD Worx is prioritizing the kinds of collaborations across platforms that spark success among contact center agents, and translate to faster issue resolution for clients. We’re proud to partner with Microsoft and SD Worx to deliver exceptional CX for millions of employees every month.”

Additional Resources

Social Networks

About Talkdesk

Talkdesk® is a global cloud contact center leader for customer-obsessed companies. Our automation-first customer experience solutionsoptimize our customers’ most critical customer service processes. Our speed of innovation, vertical expertise, and global footprint reflect our commitment to ensuring that businesses can deliver better experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.

About Microsoft

Microsoft (Nasdaq “MSFT” @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

About the Talkdesk partner ecosystem:

The Talkdesk global ecosystem represents a diverse network of best-in-class resellers, strategic alliance partners, cloud distributors, and technology vendors focused on providing a better way for organizations to create more meaningful and memorable moments with their customers. These partners support Talkdesk in helping customers across industries and around the world deliver customer experiences that build trust and loyalty.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

EMEA
Samantha Cupples
samantha.cupples@talkdesk.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 18:27:00 CEST | Press release

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r

Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 18:00:00 CEST | Press release

Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with

Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies18.8.2022 15:49:00 CEST | Press release

Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing. “Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom